Research programme: neurodevelopmental-disorders therapeutics - Ractigen Therapeutics/ University Medical Center Utrecht

Latest Information Update: 07 Feb 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

29 Jan 2024 Ractigen Therapeutics enters into R&D agreement with University Medical Center Utrecht for the development of for the development of neurodevelopmental disorder therapeutics
29 Jan 2024 Early research in Neurodevelopmental disorders in China (Parenteral)
17 Oct 2019 Ractigen Therapeutics has patent protection for 'Novel small activating RNA' in Canada

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com